Nachrichten zur Abbvie Inc. Aktie

Heres Why AbbVie (ABBV) Fell More Than Broader Market

In the most recent trading session, AbbVie (ABBV) closed at $185.48, indicating a -2.82% shift from the previous trading day.…

Democrats press Pfizer, J&J and others over low tax bills and lobbying as Senate debates Trumps plan

The lawmakers accuse Pfizer, Merck, J&J, AbbVie and Amgen of paying little to nothing in federal taxes despite generating billions…

Pfizer, AbbVie und Co unter Druck: Trump mit dem nächsten Hammer?

US-Präsident Donald Trump will der Pharma-Industrie weiter an den Kragen gehen. Laut Kreisen möchte der Republikaner die Pharmawerbung in den…

Pfizer, AbbVie und Co unter Druck: Trump mit dem nächsten Hammer?

US-Präsident Donald Trump will der Pharma-Industrie weiter an den Kragen gehen. Laut Kreisen möchte der Republikaner die Pharmawerbung in den…

AbbVies Venclexta Misses Goal in Myelodysplastic Syndromes Study

Venclexta fails to meet survival goals in ABBVs phase III MDS study, marking another clinical setback for the cancer drug.…

AbbVies Diversification Strategy Cushions Venetoclax MDS Blow

…

AbbVie fails in late-stage trial for Roche-partnered blood cancer therapy venetoclax

…

5 Large Drug Stocks That Are Poised to Ride on Sector Recovery

In the Large-Cap Pharmaceuticals industry, AbbVie, Novartis, Pfizer, Sanofi and Bayer are worth retaining amid macro pressure and rising innovation.…

2 High-Yielding ETFs That Can Generate Dividend Income for Your Portfolio for Decades

Investing in dividend stocks is a great way to generate a steady stream of recurring income for your portfolio. But…

AbbVie (ABBV) Gains As Market Dips: What You Should Know

The latest trading day saw AbbVie (ABBV) settling at $191.50, representing a +1.06% change from its previous close.…

AbbVie Inc. (ABBV) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

…

AbbVie at Goldman Sachs Conference: Strategic Growth and Innovation By Investing.com

AbbVie at Goldman Sachs Conference: Strategic Growth and Innovation…

3 Stocks With Mouthwatering Dividends You Can Buy Right Now

How would you like to get paid every quarter (and sometimes every month) to own a stock? Thats exactly what…

AbbVie (ABBV) Increases Despite Market Slip: Heres What You Need to Know

The latest trading day saw AbbVie (ABBV) settling at $187.66, representing a +0.17% change from its previous close.…

AbbVie (ABBV) Gains As Market Dips: What You Should Know

The latest trading day saw AbbVie (ABBV) settling at $186.11, representing a +0.26% change from its previous close.…

Better Dividend Growth ETF: Vanguard Dividend Appreciation ETF or iShares Core Dividend Growth ETF

Dividend growth stocks can be powerful investments. Hartford Funds and Ned Davis Research dug into the data on stocks based…

Top Research Reports for Berkshire Hathaway, AbbVie & Intuitive Surgical

Berkshire Hathaway, AbbVie and Intuitive Surgical beat estimates as analysts highlight growth drivers, headwinds and strategic moves in new reports.…

CERE DEADLINE NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - CERE

NEW YORK, May 26, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,…

Elon Musk Commits to Tesla. Is That a Good Thing?

In this podcast, Motley Fool analyst Jason Moser and host Ricky Mulvey discuss: Investing in companies with a "singular" leader, like…

2 Incredible Dividend Growth Stocks to Buy Now

Dividend growth stocks have long been reliable engines of wealth creation. Historically, companies with 10-year annualized dividend growth rates above…

The Zacks Analyst Blog Highlights Bayer, Novo Nordisk, GSK, Merck and AbbVie

Bayer, Novo Nordisk, GSK, Merck and AbbVie are part of the Zacks top Analyst Blog.…

3 Magnificent Stocks That Are Passive Income Machines

Make money without even trying: Thats what passive income is all about. But good investment alternatives are required to make…

US FDA approves AbbVies drug for a type of lung cancer

The U.S. Food and Drug Administration has approved AbbVies drug to treat adults with a type of lung cancer who…

AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know

AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware…

1 No-Brainer Dividend Index Fund to Buy Right Now for Less Than $500 -- and Another Dividend Fund Yielding 11%

Two of the best things in the investment world are index funds and dividend-paying stocks. So an even better thing,…

Recession Worries? Heres 1 of the Best Dividend Stocks for Turbulent Times

J.P. Morgan stated last month that it believes there is a 60% chance of a recession in 2025 due to…

2 High-Yield Dividend Stocks to Buy in May and Hold Forever

When investing in dividend stocks, paying attention to the right things is essential. A high yield can be attractive, but…

AbbVie Aktie: Es läuft wie geschmiert

Wien (www.aktiencheck.de) - AbbVie-Aktienanalyse von der Raiffeisen Bank International AG: Raphael Schicho, Analyst der Raiffeisen Bank International AG (RBI), nimmt in…

Here Are All the Dividend Kings Beating the S&P 500 in 2025 -- and the 2 That Are the Best Stocks to Buy Now

The S&P 500 has bounced back somewhat after sinking nearly 19% below its previous high following President Trumps "Liberation Day"…

Is the Trump Administration About to Cause AbbVie, Eli Lilly, and Johnson & Johnson Stocks to Crash?

Investors often view Pharmaceutical stocks as safe havens during periods of market turbulence. Stock market volatility or even economic downturns…

Why AbbVie Stock Trounced the Market Today

The positive, post-earnings momentum lifting AbbVies (NYSE: ABBV) stock price continued on Monday. The veteran healthcare companys shares booked a…

Want to Avoid the "Magnificent Seven" and Generate Passive Income? This Vanguard ETF May Be for You

The "Magnificent Seven" -- Apple, Microsoft, Nvidia, Amazon, Alphabet, Meta Platforms, and Tesla -- took the market by storm in…

3 Dividend Stocks to Buy and Hold for the Next Decade

Many income investors would love to have a low-maintenance portfolio that doesnt require constant attention. Theyd prefer to buy great…

Should Investors Be Worried About Dividend King AbbVie?

Nearly everything looked great with AbbVies (NYSE: ABBV) first-quarter results. The big drugmakers revenue jumped 8.4% year over year, thanks…

Medikamentenumsätze höher als erwartet! AbbVie legt kräftig zu und erhöht Gewinnprognose für 2025!

Das Pharmaunternehmen AbbVie (ABBV) hat am Freitag, den 25. April 2025, vor Börsenbeginn seine Geschäftszahlen für das 1. Quartal 2025…

Why AbbVies Stock Is A Strong Buy After Q1 2025 Results

…

4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off

Its always a good time to buy solid dividend stocks, but considering the challenging economic environment, now might be a…

2 Outstanding Dividend Stocks to Buy and Hold For 20 Years

Many investors are withdrawing their money from the stock market right now, but those focused on the long term know…

Why AbbVie Stock Topped the Market Today

A pair of convincing quarterly earnings beats -- not to mention a profitability guidance raise -- made AbbVie (NYSE: ABBV)…

AbbVies First Quarter Beat And Raise Leaves Room For More

…

AbbVie: Q1 Earnings Reinforce Positive Momentum

…

AbbVie Beats on Q1 Earnings & Sales, Raises 25 EPS View

ABBVs first-quarter earnings and sales beat estimates. The company raises its EPS guidance based on the strong sales performance of…

Lowey Dannenberg Notifies Cerevel Therapeutics Holdings, Inc. (“Cerevel” or the “Company”) (NASDAQ: CERE) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm

NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress…

dpa-AFX ProFeed